Next steps after strong bone-building therapy
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism clinical trials.
This study looks at what medicine works best for women who have finished a 1-year course of a strong bone-building drug (romosozumab or teriparatide) for severe osteoporosis. The goal is to find a good follow-up treatment to keep bones strong and prevent fractures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman after menopause
- You have severe osteoporosis and just finished a full course of either romosozumab or teriparatide
- You do not have other bone diseases besides postmenopausal osteoporosis
- You have not taken other bone-affecting medications (like bisphosphonates) in the last year
- Your kidneys are working well enough (creatinine clearance at least 60)
- You do not have liver failure, any cancer, or uncontrolled endocrine diseases
- Your vitamin D level is at least 20 ng/mL
- You are not allergic to denosumab, zoledronate, teriparatide, or romosozumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
This study looks at what changes in the body after starting romosozumab (an osteoporosis treatment) in postmenopausal women at higher risk for fractures. Researchers want to understand the treatment’s “mechanism,” which may help improve future osteoporosis care.
This study looks at how well your blood vessels work and how strong your muscles are, in women after menopause with osteoporosis. You may be asked to start standard osteoporosis treatment, and the researchers will study pain and changes related to vascular function and sarcopenia (loss of muscle and strength).
This study compares two treatments for osteoporosis in postmenopausal women: a sequence of romosozumab followed by denosumab versus zoledronic acid alone. The goal is to see which approach better improves bone density in the hip. Participants will receive either the combination or the single drug for a period, and their progress will be monitored.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
Hear when a new Osteoporosis, Postmenopausal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.